Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vimentin Expression-based Therapeutic Response in Triple Negative Breast Cancer Receiving Combination of Simvastatin and NAC: A Randomized, Double-Blind, Placebo-Controlled Trial

NCT05550415 is registered in ClinicalTrials.gov with Universitas Indonesia as lead sponsor.

NCT NCT05550415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05550415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vimentin Expression-based Therapeutic Response in Triple Negative Breast Cancer Receiving Combination of Simvastatin and NAC: A Randomized, Double-Blind, Placebo-Controlled Trial
Lead sponsor
Universitas Indonesia
Phase
Phase 2
Overall status
Recruiting
Start date
August 19, 2022
Completion date
December 31, 2026
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, simvastatin adverse reaction, triple negative breast cancer